Entrada Therapeutics expects cash to fund requirements into 2H25

Cash, cash equivalents and marketable securities were $188.7 million as of December 31, 2022, compared to $215.6 million as of September 30, 2022 and $291.1 million as of December 31, 2021. The Company anticipates that its existing cash, cash equivalents and marketable securities, together with the proceeds received under the Vertex Agreement, ongoing research support and the anticipated achievement of certain near-term milestones under the Vertex Agreement will be sufficient to extend our cash runway into the second half of 2025, supporting the Company’s expansion and continued development of EEV-therapeutic candidates targeting Duchenne as well as other indications beyond neuromuscular diseases.